Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I agree that sponsor should publish clinical data, good or bad. But if Kevetrin is not working at all, Leo would not mention the request for a presentation in a PR. CTIX would do it quietly instead. To me the most telling part of the PR is:

“With that in mind, we are analyzing the collective preliminary data from the trial to date showing a strong safety profile for Kevetrin, an effect on p53 and data seeming to indicate that ovarian, pancreatic and other FDA designated orphan cancers would be ideal mid-stage clinical trial targets as we plan to move forward.”

I am expecting at least three Phase 2 trials of K against different solid tumors. Just my two cents.

And the fact that DF asked the company for an article on K's PK/PD is not definitively bullish to me. Researchers want trial results published, period.